| FORM 4 | 4 |
|--------|---|
|--------|---|

| Check this box if no |
|-----------------------|
| longer subject to |
| Section 16. Form 4 or |
| Form 5 obligations |
| may continue. See |
| Instruction 1(b). |

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

02)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| (Print of Type Responses) | | - | | | | | | | | | |
|---|---------------------------------------|--|--------|------------|---|------------------|---|--|--|--|--|
| 1. Name and Address of Reporting F Avgerinos George | 2. Issuer Name a Fortress Biotect | | | | mbol | 1 | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner | | | | |
| (Last) (First) C/O FORTRESS BIOTECH, II COLUMBUS CIRCLE, 15TH | · · · · · · · · · · · · · · · · · · · | 3. Date of Earliest Transaction (Month/Day/Year) 08/21/2015 | | | | | | X Officer (give title below) Other (specify below) SVP, Biologics Operations | | | |
| (Street) NEW YORK, NY US 10019 | 4. If Amendment, | Date Orig | inal I | Filed(Mont | h/Day/Y | | 6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | |
| (City) (State) | (Zip) | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | |
| 1.Title of Security (Instr. 3) | | Execution Date, if | | ction | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) | 6. Ownership Form: | 7. Nature of Indirect Beneficial | |
| | | (Month/Day/Year) | Code | V | Amount | (A) or (D) | Price | (Instr. 3 and 4) | Direct (D) or Indirect (I) (Instr. 4) | Ownership (Instr. 4) | |
| Common Stock, par value \$0.001 | 08/21/2015 | | D | | 10,000 | D | \$ 2.5458 (<u>1)</u> | 286,734 | D | | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1474 (9-Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

| (<i>e.g.</i> , puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | |
|---|-------------|------------------|--------------------|------------|-----------|---------|-----|--------------|--------------------|--------|---------|-------------|----------------|-------------|-------------|
| 1. Title of | 2. | 3. Transaction | 3A. Deemed | 4. | 5. | Numl | ber | 6. Date Exer | cisable | 7. Tit | le and | 8. Price of | 9. Number of | 10. | 11. Nature |
| Derivative | Conversion | Date | Execution Date, if | Transactio | n of | 2 | | and Expirati | on Date | Amo | unt of | Derivative | Derivative | Ownership | of Indirect |
| Security | or Exercise | (Month/Day/Year) | any | Code | D | erivati | ive | (Month/Day | /Year) | Unde | rlying | Security | Securities | Form of | Beneficial |
| (Instr. 3) | Price of | | (Month/Day/Year) | (Instr. 8) | Se | ecuriti | es | | | Secu | rities | (Instr. 5) | Beneficially | Derivative | Ownership |
| | Derivative | | | | A | cquire | d | | | (Instr | . 3 and | | Owned | Security: | (Instr. 4) |
| | Security | | | | (A | A) or | | | | 4) | | | 0 | Direct (D) | |
| | | | | | | ispose | d | | | | | | * | or Indirect | |
| | | | | | | (D) | | | | | | | Transaction(s) | < / . | |
| | | | | | | nstr. 3 | | | | | | | (Instr. 4) | (Instr. 4) | |
| | | | | | 4, and 5) | |) | | | | | | | | |
| | | | | | | | | | | | Amount | | | | |
| | | | | | | | | Date | Expiration | | or | | | | |
| | | | | | | | | Exercisable | Expiration Date | Title | Number | | | | |
| | | | | | | | | Excicisable | Date | | of | | | | |
| | | | | Code V | / (/ | A) (I | D) | | | | Shares | | | | |

Reporting Owners

| Densetter Orene Name (Address | Relationships | | | | | | | | |
|--|---------------|-----------|---------------------------|-------|--|--|--|--|--|
| Reporting Owner Name / Address | Director | 10% Owner | Officer | Other | | | | | |
| Avgerinos George C/O FORTRESS BIOTECH, INC. 3 COLUMBUS CIRCLE, 15TH FLOOR NEW YORK, NY US 10019 | | | SVP, Biologics Operations | | | | | | |

Signatures

08/25/2015 /s/ S. Halle Vakani, Attorney-in-Fact

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This transaction was executed in multiple trades at prices ranging from \$2.51 to \$2.63. The price reported in Column 4 is a weighted average price. The reporting person (1) hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the trades were effected.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.